Co-director: Bryan Bednarz, PhD
Associate Professor
Departments of Medical Physics and Human Oncology
Co-director: Joseph Grudzinski, PhD
Senior Scientist
Radiological Engineering and Design Laboratory
Department of Radiology
Summary
The Advanced Imaging and Dosimetry Core (AIDC) will provide dedicated expertise and cost-efficient support required to facilitate quantitative multiscale imaging and dosimetry calculations for the P01 application, “Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response.” This centralized dosimetry service core is critical for the P01 to achieve its overarching research goals of 1) developing a broad mechanistic understanding of the immunomodulatory capacity of molecular targeted radionuclide therapy (TRT) and 2) evaluating TRT as part of the next generation immunotherapy approaches to improve the treatment of immunologically “hot” and “cold” tumors.
Specific Aims
-
Support investigators in all stages of the imaging and dosimetry process, including experimental design, image acquisition optimization, pharmacokinetic profiling and modeling, micro- and macroscopic 3D dose calculations, and treatment response assessment.
-
Develop and apply calibration and quality assurance protocols throughout the quantitative imaging and dosimetry workflow that limit uncertainties in the critical stages of the process.
-
Establish a radiopharmaceutical treatment planning workflow using rodent cancer models and companion animals with spontaneous cancer that will ultimately translate to use in humans.
AIDC Team
David Adam
Graduate Student
Department of Medical Physics
Ohyun Kwon
Graduate Student
Department of Medical Physics
Learn More
The Advanced Imaging and Dosimetry Core (AIDC) provides the infrastructure, resources, and expertise required to facilitate quantitative multiscale imaging and dosimetry calculations, which are required to optimally synergize the combination of molecular targeted radionuclide therapy (TRT) and immunotherapy (ImmRx). The AIDC is a centralized dosimetry service that ensures consistent scientific rigor and dosimetry reporting across each of the Projects of this PO1 proposal, entitled “Molecular targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy response”. Furthermore, the significance of centralizing this process for each Project is the tremendous gains in efficiency that are achieved, ultimately saving individual investigators time and effort. Additionally, the AIDC will expand the leadership and operation of the Small Animal Imaging and Radiotherapy Facility (SAIRF) by offering support in all stages of the imaging and TRT dosimetry process, including calibration, experimental design, image acquisition optimization, pharmacokinetic profiling and modeling, micro-and macroscopic 3D dose calculations, and treatment response assessment. The AIDC emphasizes quality assurance and quality control in all aspects of the imaging and dosimetry process so that results are validated for application to the FDA. The AIDC collaborates closely with the Radionuclide Production and Radiochemistry Core (RPRC) for dose calibration and traceability of the radiopharmaceuticals; and, the AIDC collaborates with the Biostatistics and Bioinformatics Core (BBC) to help interpret imaging and dosimetry findings to validate response assessment. Lastly, the AIDC will help investigators disseminate their findings to the scientific community through publications and conference presentations. Renowned experts in the field of TRT dosimetry, Professor Bryan Bednarz and Joseph Grudzinski, lead administrative and technical efforts, respectively.